The present invention is directed to the prophylatic field treatment of photodamaged skin with topical ingenol mebutate. More specifically, the present invention concerns field-directed treatment of UV-damaged skin with topical ingenol mebutate for reducing the number of skin lesions that emerge from the UV-damaged skin over time. In addition, the present invention concerns field-directed treatment for removing photodamaged skin, mutated keratinocytes, cutaneous immunosuppressive environments and/or p53+ patches caused by UV with topical ingenol mebutate. By way of example, the present invention is directed to treating photodamaged skin with topical ingenol mebutate at about 0.05% concentration. The present invention is also concerned with the treatment of SCC tumors with topical ingenol mebutate for reducing the number of SCC tumors. By example, the present invention is directed to treating and curing SCC xenografts with topical ingenol mebutate at about 0.25% concentration. The present invention is further directed to a topical field-directed treatment for the removal of tattoos from skin with ingenol mebutate. By way of example, the present invention is directed to removing tattoos with topical ingenol mebutate at concentrations of up to about 0.25%.La présente invention a trait au traitement de terrain prophylactique de la peau endommagée par la lumière avec du mébutate dingénol topique. De manière plus spécifique, la présente invention concerne le traitement de terrain de la peau endommagée par lUV avec du mébutate dingénol topique pour réduire le nombre de lésions de la peau qui émergent depuis la peau endommagée par la lumière dans le temps. La présente invention concerne également le traitement de terrain pour lélimination de peau endommagée par la lumière, de kératinocytes mutées, denvironnements cutanés immuno-suppressifs et/ou de foyers de cellules p53+ provoqués par lUV avec du mébutate dingénol topique. Selon un mode de réalisation, la présente inventio
